GlassScriptPhysician profile
Jerald Zimmerman
NPI 1255384624
$1,116.73
in general payments reported to CMS, 2019-2025
28 companies · $143 in 2025
The $143 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $104 · 2021: $142 · 2022: $63.70 · 2023: $102 · 2024: $292 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $174.56 | 2019-2023 | Spravato |
| Merck Sharp & Dohme LLC | $107.08 | 2021-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Collegium Pharmaceutical, INC. | $97.68 | 2022-2025 | Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.80 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Otsuka America Pharmaceutical, INC. | $68.54 | 2023-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $54.71 | 2019-2020 | |
| Novo Nordisk INC | $49.36 | 2023-2025 | |
| Digital Diagnostics INC. | $49.33 | 2019 | |
| Depuy Synthes Sales INC. | $41.68 | 2019-2024 | Monovisc |
| Amgen INC. | $41.18 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $36.25 | 2019 | |
| Exact Sciences Corporation | $35.56 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $34.27 | 2024 | Lokelma, Farxiga |
| Boston Scientific Corporation | $29.75 | 2024 | Emblem Mri S-Icd |
| Arbor Pharmaceuticals, INC. | $29.01 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $20.77 | 2020 | |
| Abbott Laboratories | $16.39 | 2021 | |
| Glaxosmithkline, LLC. | $15.56 | 2024 | Trelegy Ellipta |
| Amarin Pharma, INC. | $14.97 | 2019 | |
| Pfizer INC. | $14.57 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $14.46 | 2024 | Iovera, Zilretta |
| Alk-Abello, INC | $14.32 | 2024 | Odactra, Ragwitek, Grastek |
| Xeris Pharmaceuticals, INC. | $14.29 | 2024 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $12.78 | 2020 | |
| Lundbeck LLC | $12.50 | 2020 | |
| Almatica Pharma LLC | $12.48 | 2022 | |
| Sun Pharmaceutical Industries INC. | $11.97 | 2021 | |
| Mylan Specialty L.P. | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerald Zimmerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.